Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B₂ receptor antagonism

Constanze A. Jakwerth¹ · Martin Feuerherd² · Ferdinand M. Guerth¹ · Madlen Oelsner¹ · Linda Schellhammer³ · Johanna Giglberger¹,⁶ · Lisa Pechtold⁶ · Claudia Jerin¹,⁶ · Luisa Mogler⁶ · Bernhard Haller³ · Anna Erb¹ · Barbara Wollenberg⁶ · Christoph D. Spinner⁷ · Ulrike Protzer² · Carsten B. Schmidt-Weber¹ · Carsten B. Schmidt-Weber¹ · Ulrich M. Zissler¹ · Adam M. Chaker¹,⁶

Received: 28 December 2021 / Revised: 7 February 2022 / Accepted: 15 February 2022 / Published online: 5 March 2022
© The Author(s) 2022

Abstract

SARS-CoV-2 has evolved to enter the host via the ACE2 receptor which is part of the kinin-kallikrein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV-2-infection and epithelial mechanisms of the kinin-kallikrein-system at the kinin B₂ receptor level in SARS-CoV-2-infection that is of direct translational relevance. From acute SARS-CoV-2-positive study participants and -negative controls, transcriptomes of nasal curettages were analyzed. Primary airway epithelial cells (NHBEs) were infected with SARS-CoV-2 and treated with the approved B₂R-antagonist icatibant. SARS-CoV-2 RNA RT-qPCR, cytotoxicity assays, plaque assays, and transcriptome analyses were performed. The treatment effect was further studied in a murine airway inflammation model in vivo. Here, we report a broad and strong upregulation of kallikreins and the kinin B₂ receptor (B₂R) in the nasal mucosa of acutely symptomatic SARS-CoV-2-positive study participants. A B₂R-antagonist impeded SARS-CoV-2 replication and spread in NHBEs, as determined in plaque assays on Vero-E6 cells. B₂R-antagonism reduced the expression of SARS-CoV-2 entry receptor ACE2, G protein–coupled receptor signaling, and ion transport in vitro and in a murine airway inflammation model in vivo. In summary, this study provides evidence that treatment with B₂R-antagonists protects airway epithelial cells from SARS-CoV-2 by inhibiting its replication and spread, through the reduction of ACE2 levels and the interference with several cellular signaling processes. Future clinical studies need to shed light on the airway protection potential of approved B₂R-antagonists, like icatibant, in the treatment of early-stage COVID-19.

Key messages
• Induction of kinin B₂ receptor in the nose of SARS-CoV-2-positive patients.
• Treatment with B₂R-antagonist protects airway epithelial cells from SARS-CoV-2.
• B₂R-antagonist reduces ACE2 levels in vivo and ex vivo.
• Protection by B₂R-antagonist is mediated by inhibiting viral replication and spread.

Keywords ACE2 · COVID-19 · Kinin · B₂R-antagonist · Kinin-kallikrein-system · SARS-CoV-2

Abbreviations
ACE2 Angiotensin-converting enzyme 2
ant-B₂R Kinin B₂ receptor antagonist
BDKRB1 Kinin B₁ receptor (gene name)
BDKRB2 Kinin B₂ receptor (gene name)
B₁R Kinin B₁ receptor
B₂R Kinin B₂ receptor
B₂R-antagonist Kinin B₂ receptor antagonist
CAS Contact-activation-system

Ulrich M. Zissler and Adam M. Chaker are senior authors that contributed equally to the work.

Constanze A. Jakwerth and Martin Feuerherd contributed equally to the work.

Carsten B. Schmidt-Weber
csweber@tum.de

Extended author information available on the last page of the article
COVID-19 | Coronavirus disease of 2019
DABK | Des-Arg9-bradykinin
GPCR | G protein–coupled receptor
HC | Hydrocortisone
HMWK | High-molecular-weight-kininogen
IC50 | Half maximal inhibitory concentration
KKS | Kinin-kallikrein-system
LDH | Lactate dehydrogenase
LMWK | Low-molecular-weight-kininogen
NHBE | Normal human bronchial epithelial cells
RAS | Renin-angiotensin-system
SARS-CoV-2 | Severe acute respiratory syndrome coronavirus-2
TMPRSS | Transmembrane serine protease

Introduction

SARS-CoV-2 vaccines have been approved worldwide since the end of 2020 and are starting to show their protective effects in public health [1, 2]. Even with vaccines at hand, an important medical need for therapeutic approaches for COVID-19 remains: immunocompromised individuals may not mount a sufficient immune response after vaccination and escape variants, such as the currently spreading SARS-CoV-2 variant Omicron [3], may breach protection afforded by the vaccines [4–7].

Key factors for SARS-CoV-2 cell entry are two cell surface molecules, angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease (TMPRSS) [8]. TMPRSS2 cleaves the coronaviral spike protein and primes it for cell fusion, while ACE2 enables the virus particle to enter the cell by binding of its spike protein [9, 10]. The latter acts as central component in its function as terminal carboxypeptidase in the counter-regulatory axis of the renin-angiotensin-system (RAS) and the contact-activation-system (CAS) [8, 11], which initiates blood coagulation and can additionally activate the kinin-kallikrein-system (KKS) [12]. In its role in the RAS, ACE2 has anti-vasoconstrictive and anti-inflammatory effects by hydrolyzing the vasoconstrictive and tissue-damaging angiotensin II, which contributes to airway remodeling and fibrosis [13, 14], to angiotensin (1–7) [15]. In its role in the KKS, ACE2 further hydrolyzes vasoactive peptides such as des-Arg9-bradykinin (DABK), which activates the pro-inflammatory axis of the KKS [16] via the inducible kinin B1 receptor (BDKRB1; B1 receptor; B1R) [17]. While DABK is the ligand of B1R, bradykinin, the end product of the KKS-cascade, activates the constitutively expressed kinin B2 receptor (BDKRB2; B2 receptor; B2R) [18]. Through this mechanism, bradykinin mediates its pro-inflammatory effects by eliciting a variety of responses, including vasodilation and edema, via the G protein–triggered phosphatidylinositol-calcium second messenger-system [19–23]. The fact that SARS-CoV-2 utilizes ACE2 to enter airway cells along with the fact that ACE2 is a multifunctional enzyme that counter-regulates the ACE-driven mechanisms of the RAS and balances the KKS may therefore explain the serious course of COVID-19, not only in the lungs but systemically [24, 25].

Recent publications suggest that the KKS could play a role in COVID-19. KKS comes into play particularly in connection with the high prevalence of thromboembolic events in severely ill COVID-19 patients [7, 17, 26–28]. A recent study on a cohort of 66 COVID-19 patients admitted to the intensive care unit showed that the KKS was strongly activated, which was reflected in the consumption of factor XII (F12), pre-kallikrein (KLKB1), and high-molecular-weight-kininogen (HMWK; KNG1) [26]. When activated, plasma-kallikrein (KLKB1) releases kinins from HMWK (KNG1) in the peripheral blood. In tissues, however, the functional real tissue kallikrein (KLL1) generates bradykinin and kallidin [29], but by cleavage of low-molecular-weight-kininogen [30], which is an additional splice product of the KNG1 gene [31, 32]. It has further been hypothesized that kinin-dependent “local lung angioedema” involving B1R and B2R is an important characteristic of COVID-19 [33–36]. This study examines the potential of an intervention in the KKS at the kinin receptor level in SARS-CoV-2-infection with translational relevance and reveals an antiviral and protective effect of B2R-antagonism on human bronchial epithelium.

Materials and methods

Human study participants and nasal brushings

Nasal brushings were performed as part of a larger healthcare professional observational cohort study, which was approved by the Ethics Commission of the Technical University of Munich (AZ 175/20 s) during the first COVID-19 wave in Germany in 2020. Nasal brushings were obtained from 7 healthy healthcare professionals and 4 healthcare professionals with new onset of mild to moderate respiratory symptoms and within 2 days of newly confirmed SARS-CoV-2 diagnosis. No vaccine or specific treatment was available at the time of sampling. RNA was extracted from these nasal brushings and subjected to whole-genome transcriptome analysis (see Supp. Info.). All participants gave written informed consent prior to participation (Table 1).

In vivo mouse study

Mice received murine IL-12Fc (1 μg protein in 50 μL PBS) or PBS control intranasally [37]. Intranasal application was performed under isoflurane anesthesia in two steps of 25 μL per nostril. Forty-eight hours later, the mice received a single
subcutaneous injection of icatibant (2 nmol per 10 g body weight; HOE-140 ((icatibant), H157, SLBX4410, Sigma) or PBS control. The experiment was terminated by CO₂ asphyxiation 6 h or 24 h after injection of icatibant. The experiment was carried out twice. Organs were snap frozen for protein extraction. Experiments were pre-registered at www.animalstudyregistry.org (study title “Effect of drug on ACE2 levels in mice”; https://doi.org/10.17590/ars.0000225). Mice enrolled in the experiment were 6–8 weeks old, from either C57BL/6 J, BALB/c, or C3H HeN strains. Both sexes were included for each strain and means of old, from either C57BL/6 J, BALB/c, or C3H HeN strains.

Table 1  Demographic data of healthcare professional cohort

| Parameter      | Negative (n = 7) | Positive acute (n = 4) | p-value |
|----------------|------------------|------------------------|---------|
| Age (years)*   | 35.86 ± 3.86     | 37.50 ± 8.78           | n.s.    |
| Sex (m/f)      | 2/5              | 1/3                    |         |
| IgM (ng/mL)    | 1.32 ± 0.28      | 4.34 ± 2.81            | n.s.    |
| IgG (ng/mL)    | 0.48 ± 0.08      | 67.08 ± 19.51          | 0.0061  |

*At informed consent procedure and inclusion into study

Results

B₂ receptor antagonist inhibits replication and spread of SARS-CoV-2

ACE2 is the central viral entry receptor for SARS-CoV-2 on human epithelial cells of the respiratory tract [8]. Recent studies showed that this receptor and its co-receptors are not only expressed in the lower airways, and thus on alveolar epithelial cells type-I and -II, but are also present in the upper airways, but predominantly in the nasal mucosa [38].

To investigate local effects of the acute SARS-CoV-2-infection on the nasal epithelium, we analyzed the transcriptome of nasal curetages from symptomatic study participants, who tested acutely positive for SARS-CoV-2 (n = 4), and from SARS-CoV-2-negative study participants (n = 7). In a transcriptome analysis, the most strongly induced genes encoding secreted factors included many members of the kallikrein family (Fig. 1A, Table S1), in particular the kallikreins KLK5, KLK9, and KLK12 (Fig. 1B, Table S2). Next, we focused on the central factors of the tissue-KKS as stated above. Two-thirds of the genes were upregulated including the precursor of bradykinin LMWK (KNG1), true tissue kallikrein (KLK1), responsible of hydrolyzing LMWK to kallidin/bradykinin, and further the receptor for bradykinin, B₂R (BDKRB2), which was significantly increased (Fig. 1C, Table S3). Since the two plasma factors factor XII (F12) and pre-kallikrein (KLKB1) are mainly processed and act in the plasma-KKS, it was expected that these factors are not differentially expressed in the nasal mucosa. The induction of KNG1, KLK1, and BDKRB2 in primary nasal samples of SARS-CoV-2-positive study participants is evidence for an autocrine bradykinin effect via B₂R that is triggered locally during COVID-19 disease.

This finding prompted us to investigate selective kinin B₂ receptor antagonism in connection with SARS-CoV-2-infection. We therefore hypothesized that a B₂R-antagonist like icatibant, an approved compound for the treatment of hereditary angioedema [39], counter-regulates the effects of bradykinin during a SARS-CoV-2-infection and thereby has a protective effect on the integrity of the airway mucosa. To circumvent limitations of cell lines like Vero-E6, A549, or Calu-3 cells that are intrinsically impaired to form an interferon response upon viral infection [40], we infected primary human NHBEs with SARS-CoV-2.

To examine the effects of SARS-CoV-2-infection and B₂R-antagonist treatment on the microscopic integrity of the airway epithelium, 3D-air–liquid interphase organoid cultures were differentiated from primary NHBEs (Supp.Info). After complete differentiation, epithelia were pre-treated from the basal side with the approved B₂R-antagonist icatibant, and subsequently infected with SARS-CoV-2 from the apical side. The cultures pre-treated with B₂R-antagonist showed less virus-induced balloon-like structures compared to untreated cultures. The epithelial layers remained qualitatively more intact, which indicates a protective effect of the B₂-R-antagonist for the bronchial epithelium (Fig. 1D). This finding was further strengthened by cytotoxicity assays: the B₂-R-antagonist had no toxic effects on NHBEs even at high doses determined by lactate
Induction of kallikreins and kinin receptor B2 in the nasal mucosa of acutely positive COVID-19 study participants. A Volcano plot of significantly differentially regulated genes (DEGs = differentially expressed genes) in nasal curettings of study participants that were acute positive for SARS-CoV-2 compared to healthy individuals (negative) using human miR microarray technology. Highlighted genes have a fold change (FC) \( \geq 10 \) with \( P < 0.05 \); genes in red are upregulated; genes in blue are downregulated; genes in green are unchanged. Heat map of gene expression analysis of kallikrein genes and C of genes of the kinin-kallikrein-system (KKS) in nasal curettings comparing acute SARS-CoV-2-positive study participants to healthy controls. All entities are shown. Asterisks indicate significantly regulated genes \( (P < 0.05) \) in SARS-CoV-2-infected NHBEs compared to medium. Color code indicates Log2-fold change from low (blue) through 0 (white) to high (red). Duplicate gene names indicate the abundance of two or more isoforms of the same gene in the analysis.

3D-air–liquid interphase cultures from NHBEs were pre-treated for 24 h with/without 1 nM B2 R-antagonist from the basal side and subsequently infected with SARS-CoV-2 for 48 h from the apical side. E Lactate dehydrogenase (LDH) cytotoxicity assay using the LDH Cytotoxicity Detection Kit PLUS studying the effect of increasing doses of the B2 R-antagonist after 48 h in primary NHBEs from 4 donors. Results are depicted as mean ± s.e.m. Statistical tests compared each dose of B2 R-antagonist with 0 nM B2 R-antagonist. F Cytotoxicity assay determining LDH release into the supernatants of cultures of SARS-CoV-2-infected NHBEs from 12 donors that were pre-treated for 24 h with/without 1 nM B2 R-antagonist. G Quantification of infectious particles in the supernatants of SARS-CoV-2-infected NHBEs from 10 donors that were pre-treated with/without 1 nM B2 R-antagonist for 24 h. Supernatants were titrated onto fresh Vero-E6 cells and plaque assay was quantified 24 h later. Results are depicted as plaque-forming units (PFU) per milliliter. H qPCR analysis of total SARS-CoV-2 RNA (viral genome and transcripts, which all contain the N1 sequence region) normalized to human ACTB of SARS-CoV-2-infected primary NHBE after 24 h of pre-treatment with/without 1 nM B2 R-antagonist followed by 24 h of SARS-CoV-2 inoculation. For Fig. 1E, F, and H, statistical tests compared SARS-CoV-2-infected versus uninfected samples or B2 R-antagonist-treated versus untreated samples. I Analysis of human ACE2 gene expression using qPCR \( (n=10) \) and J of human ACE2 protein levels analyzed by ELISA from cell lysates \( (n=6) \) after 24 h of pre-treatment of NHBEs with/without 1 nM B2 R-antagonist, followed by SARS-CoV-2 inoculation for 24 h.

dehydrogenase (LDH) release, but rather exhibited a cell-protecting effect in uninfected cells (Fig. 1E) and during SARS-CoV-2-infection (Fig. 1F). Next, the supernatants of pre-treated, infected primary NHBEs were collected and titrated onto fresh Vero-E6 cell cultures and plaque assays were performed. Strikingly, we found that in vitro treatment of NHBEs with B2 R-antagonist prior to infection reduced the number of plaque-forming units (PFU) in a plaque assay by 87% (Fig. 1G). The levels of total SARS-CoV-2-RNA in cells that had been pre-treated with the B2 R-antagonist decreased by 52% compared to untreated infected NHBEs (Fig. 1H). With regard to the virus entry process, ACE2 was reduced by pre-treatment with B2 R-antagonist at the mRNA level (Fig. 1I), but just in trend at the protein level (Fig. 1J). However, ACE2 protein levels were significantly reduced upon SARS-CoV-2-infection. The membrane-standing protease TMPRSS2 cleaves the spike protein for SARS-CoV-2 and primes it for optimized binding to its entry receptor ACE2. In contrast to ACE2, TMPRSS2 transcript levels were significantly increased in infected compared to uninfected NHBEs but were not affected by B2 R-antagonist pre-treatment (Fig. 2A). Further experiments on the B2 R-antagonist effect on the SARS-CoV-2-infection of NHBE showed that pre-treatment with B2 R-antagonist significantly reduced infection-mediated cytotoxicity measured by LDH release (Fig. 1F).

Repetitive treatment with B2 R-antagonist inhibits SARS-CoV-2-replication and spread post-infection

The finding that B2 R-antagonism leads to a downregulation of ACE2 protein levels in lung epithelial cells was confirmed in vivo in a murine airway inflammation model. To mirror COVID-19 pathogenesis, mice were treated with IL-12, which mimics virus-induced airway inflammation via activation of the IL-12/IFN-γ-axis [37, 41]. Specifically, mice received intranasal murine IL-12Fc, to generate a pro-inflammatory state in the lungs. The experiment was designed in two blocks of 24 sex-matched mice from three different strains per group, to rule out any confounding genetic effect. After 48 h, mice were injected subcutaneously (s.c.) with the B2 R-antagonist and the experiment was terminated 6 h or 24 h later to analyze ACE2 protein levels in the lungs. IL-12Fc pre-treated mice, which were then further treated with the B2 R-antagonist on day 2, showed reduced ACE2 protein levels in the lungs after 6 h compared to control mice, which were only treated with PBS on day 2 (Fig. 2A). This effect decreased after 24 h.

Anticipating treatment of SARS-CoV-2-infected study participants with the B2 R-antagonist icatibant, NHBEs were first infected with SARS-CoV-2 and then treated with the B2 R-antagonist 6 h after infection. Confirming the results of pre-treatment, post-infection treatment with the B2 R-antagonist also attenuated the cytopathic effect of SARS-CoV-2 (Fig. 2B) and reduced the number of PFU in a plaque assay on Vero-E6 cells by 84% (Fig. 2C).

We also aimed to reflect repeated dosage [42] during treatment of early infection by treating NHBEs post-infection every 24 h with B2 R-antagonist repeatedly for a period of 96 h, reflecting the drug administration of this particular substance in real life. In cells treated post-infection with 100 nM icatibant for 48 h, total viral RNA (Fig. 2D–F IC50 (total RNA 48 h) = 92.93; IC50 (total RNA 72 h) = 91.56) and also genomic viral RNA (Fig. 2G–I; IC50 (total RNA 48 h) = 7.17; IC50 (total RNA 72 h) = 7.412) were significantly reduced by 49% and 42% on average, respectively. Treatment with 1000 nM icatibant for 48 h led to a reduction of total SARS-CoV-2 RNA (Fig. 2D–F) and also of genomic SARS-CoV-2 RNA (Fig. 2G–I) by 69% and 56%.
Genomic viral RNA was detected using RT-qPCR against the sequence of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRP), which is only found in virions and during the viral replication. On the other hand, total viral RNA was detected with qPCR targeting a sequence of the SARS-CoV-2 N gene that is present in the viral genome and also in every SARS-CoV-2 protein-encoding transcript. Both, total SARS-CoV-2 RNA and genomic viral RNA levels were reduced upon treatment with the B₂R-antagonist (Fig. 2D–I).

B₂ receptor antagonism broadly silences gene expression in bronchial epithelial cells while maintaining cell-intrinsic antiviral response

Severe cases of COVID-19 develop cytokine storms [43–45] characterized by excessive systemic release of multiple cytokines including IP-10 (CXCL10), IL-6, IL-8 (CXCL8), and IL-10 [46–49]. These cases are currently treated with immunomodulating drugs, such as...
corticosteroids or biologics, like tocilizumab [50], though these treatments may interfere with or alter the antiviral immune response. We therefore compared the effect of B2R-antagonism on gene expression of SARS-CoV-2-infected bronchial epithelium with the effect of hydrocortisone. While the B2R-antagonist mainly suppressed epithelial gene expression during infection, the effects of hydrocortisone on gene induction and gene repression were comparable (Fig. 3A, Tables S4–5). This finding matches previous reports [51].

With regard to cell-intrinsic antiviral immunity, differentially expressed genes (DEGs) in NHBEs induced by SARS-CoV-2-infection included type-I and -III interferons and IFN-inducible, antiviral APOBEC genes (Fig. S1E, Table S6). SARS-CoV-2-infection particularly induced antiviral cytidine deaminases APOBEC3A and B, which we previously described to be induced by type-I interferons in the treatment of hepatitis B-virus-infection [52]. APOBEC3C mRNA levels, however, were decreased in SARS-CoV-2-infected NHBE, which could indicate a novel evasion mechanism [53]. Neither B2R-antagonist nor hydrocortisone inhibited the expression of genes with cell-intrinsic antiviral effects, but even increased the antiviral factor APOBEC3A at the mRNA level (Fig. 3B, Table S7) [54].

Our gene expression analysis shows that SARS-CoV-2-infection further induces the expression of acute-phase proteins, such as TNF-α and IL-8 (CXCL8) [55, 56], as well as IL-17C, MIP-3α (CCL20), IL-36γ [57], and chemokines CXCL1,-2,-3,-8,-17, CCL2,-3,-5 [57] in primary airway epithelial cells (Fig. 3C, Table S8). The induction of these factors most likely contributes to the recruitment and activation of relevant immune cells to the site of infection. In addition, gene expression of acute-phase proteins was not significantly affected in airway epithelial cells by B2R-antagonist or hydrocortisone treatment (Fig. 3C, Table S8).

In addition, we found that SARS-CoV-2-infection increases the expression of three known and postulated entry (co-) receptors: (1) transmembrane serine protease TMPRSS11A (Fig. S1C, Table S6, 9–13), which was described to prime the MERS coronavirus spike protein [58], (2) transmembrane serine protease TMPRSS11D, which was shown to activate SARS-CoV-2 spike protein [59], and (3) pathogen-associated molecular pattern-binding C-type lectin receptor DC-SIGN (CD209), which was described to serve as entry receptor for SARS-CoV [60] and has also been suggested as a receptor for SARS-CoV-2. The induction of these additional entry receptor candidates triggered by SARS-CoV-2-infection may potentiate the viral spread in the bronchial epithelium and thus represent a pathogenetic mechanism that needs further research.

Overall, treatment with the B2R-antagonist and hydrocortisone had no significant effects on the expression of most candidate viral entry receptors, except for hydrocortisone, which enhanced the expression of TMPRSS proteases (Fig. 3D, Table S14). In particular, when focusing on the known SARS-CoV-2 entry receptors, hydrocortisone treatment of uninfected cells was already sufficient to induce an increase in TMPRSS2 gene expression (Fig. 3E). SARS-CoV-2-infection per se also increased TMPRSS2 expression, and pre-treatment of SARS-CoV-2-infected NHBEs with hydrocortisone further potentiated this effect. On the other hand, ACE2 expression showed only a slight upward trend after hydrocortisone pre-treatment (Fig. S2B). Finally, hydrocortisone pre-treatment of SARS-CoV-2-infected NHBEs had no inhibitory effect on the release of infectious particles 24 h after infection (Fig. 3F), which was expected, since treatment of COVID-19 study participants with corticosteroids has an immunomodulatory rationale.
A - DEGs: B$_2$R-ant effect vs HC effect

B - Antiviral response

C - Acute-phase response

D - Entry Receptors

E - TMPRSS2 mRNA

F - Plaque assay
**Discussion**

Here, we provide evidence for the effect of interference with the KKS at the kinin B₂ receptor level as a means of protecting the airway epithelium from SARS-CoV-2-infection, while maintaining cell-intrinsic antiviral host response.

We initially hypothesized that through KKS interference, either feedback mechanisms or modulated signal transduction targets the virus entry receptor ACE2 and thus interferes with the spread of SARS-CoV-2. To this end, the approved B₂R-antagonist icatibant was used in this study. We demonstrate that treatment with a B₂R-antagonist inhibits the replication and spread of SARS-CoV-2 in primary airway epithelial cells, which was determined by a decrease in total and genomic SARS-CoV-2-RNA, resulting in less infectious particles in plaque assays, both when applied pre- and post-infection. While a low concentration of 1 nM B₂R-antagonist was sufficient to reduce viral RNA in primary bronchial epithelial cells when cells were treated pre-infection, 100 nM B₂R-antagonist was required to this effect, when cells were treated post-infection. In addition, the significant reduction in virus load as determined by PCR tapered off after 96 h. On the one hand, in vitro infections are performed with excess amounts of virus particles. On the other hand, the fact that, due to its constitution as a peptide analog, the B₂R-antagonist icatibant used in this study has a short half-life in the human body [42] but also pharmacological tolerance to interference at receptor level may explain why the effect reached significance after 6 h but did not persist. Therefore, it may be required to administer higher doses of the B₂R-antagonist to COVID-19 patients a few times per day to inhibit viral replication in the long term. Due to this necessary repetitive administration of the B₂R-antagonist, the monoclonal anti-plasma-kallikrein (KLKB1) antibody lanadelumab [61] may also be considered a potential pharmacologic alternative. However, it is not clear whether the effects of the B₂R blockade alone and its effects on the KKS are responsible for the SARS-CoV-2 inhibition, or whether the compound itself additionally mediates a direct antiviral effect. Therapeutic application of the B₂R-antagonist icatibant in future dose-finding studies should therefore focus on early intervention with at least two doses daily [62] and on either optimized pharmacokinetics or increased high local tissue concentrations, e.g., through topical application.

Two potential mechanisms of action for suppressing SARS-CoV-2-replication and spread in airway epithelium are revealed by this study:
membrane-bound cell surface receptor DEGs
SARS-CoV-2 + B_R-ant vs SARS-CoV-2

G protein-coupled receptor signaling pathway (GO:0007186)

Ion transport (GO:0006811)

C - Counter-regulation of SARS-CoV-2-induced DEGs by B_R antagonist

D - Membrane-bound cell surface receptors

upregulated DEGs
SARS-CoV-2 vs medium
downregulated DEGs
SARS-CoV-2 + B_R-ant vs SARS-CoV-2

medium
B_R-ant
HC
SARS-CoV-2 + B_R-ant
SARS-CoV-2 + HC

ADAM29
ANTXR1L
KCN4A
FAM26D
OR1G1
HTR1F
PRLR
CACNA11
NPP2R
TRO
ANTXR1LP1
TREM13P
<NA>
CD229
CD69
OR13C2
CASK
TAS2R41
P2RY7
SIT1
SYND631
ORS2N6
OR6K5
GRID1
ENTPD1
SLC25A2
SLC5A6
SERT
SLC7A5
TMEM126B
FCRL5
KCN5
TMEM332
CALCRL

abundance
low
high
1. Treatment with the B₂R-antagonist led to a downregulation of the viral entry receptor ACE2, in vitro in primary airway epithelial cells and in vivo in a murine airway inflammation model. Since the decrease of genomic SARS-CoV-2 RNA and total SARS-CoV-2 RNA was comparable, we conclude that the B₂R-antagonist icatibant does probably not affect the viral transcription machinery but inhibits the infection rather on the levels of entry, protein synthesis-processing, and assembly, maturation, or budding.

In comparison, the corticosteroid hydrocortisone even upregulated TMPRSS2 in infected airway epithelial cells. It is noteworthy that hydrocortisone did not change the release of infectious particles from airway epithelial cells into the supernatant. Although TMPRSS2 expression was even enhanced by hydrocortisone, our data indicate that this effect on TMPRSS2 alone is insufficient to increase susceptibility for SARS-CoV-2-infection.

2. Treatment with the B₂R-antagonist had a broad suppressive effect on gene expression of multiple cell signaling molecules, in particular on membrane-standing factors involved in GPCR signaling and ion transport.

It has recently been published that SARS-CoV-2 may use cellular GPCR signaling pathways, thereby modulate epithelial transport mechanisms involved in ion transport and thereby cause a local ion imbalance in the airways [63]. In addition, an extensive recent study described that intracellular SARS-CoV-2 protein interactions include factors involved in intracellular trafficking and transport [64]. In fact, SARS-CoV-2-infection led to a differential regulation of the gene expression of 12 potassium channel (5 upregulated/7 downregulated), 1 sodium channel (down), but in particular of 55 members of the solute carrier family (24 downregulated/31 upregulated) in primary airway epithelial cells. On the other hand, B₂R-antagonist treatment of SARS-CoV-2-infected NHBE resulted in a downregulation of 20 potassium channels and 6 sodium channels, as well as a downregulation of 29 members of the solute carrier family. We therefore conclude that B₂R-antagonism not only impedes the viral entry process by reducing ACE2, as we had hypothesized, but also counter-regulates cellular processes that include GPCR signaling and transmembrane ion transport, which SARS-CoV-2 may utilize for efficient cell entry, replication, and viral spread.

In conclusion, the results of this study suggest that B₂ receptor antagonism protects airway epithelial cells from SARS-CoV-2 spread by reducing ACE2 levels and by interfering with several cellular signaling processes. Further research is needed to elucidate more details about molecular mechanisms involved in the viral life cycle that kinin B₂ receptor antagonism targets and underlie its effects against SARS-CoV-2-infection. Based on these data, we speculate that the protective effects of B₂R-antagonism could potentially prevent the early stages of COVID-19 from progressing into severe acute respiratory distress syndrome (ARDS) with structural airway damage and fibrotic changes. We therefore propose that the safe approved B₂R-antagonist icatibant be tested in clinical trials for two important aspects: (1) Treatment of early COVID-19 disease targeting the replication and spread of the virus. (2) Optimized dosage regimen to reflect pharmacokinetics and possible pharmacological tolerance at the receptor level. Future controlled clinical trials must provide substantial evidence for optimal dosage regimen, application, efficacy, and safety to investigate, whether KKS interference at the kinin B₂ receptor level can prevent the escalation of COVID-19 to ARDS and long-term lung damage.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1007/s00109-022-02182-7.

Author contribution Study design A.M.C., C.S.W., U.P., C.A.J., M.F., U.M.Z., T.B.; collection of patient samples A.M.C., J.G., L.P., C.I.J., L.K.; conduct of experiment C.A.J., M.F., F.G., M.O., C.M., L.S., J.G., L.K.; data collection C.A.J., M.F., F.G., M.O., U.M.Z., C.M., L.S., J.G., L.P., C.I.J., L.K.; data analysis C.A.J., M.F., F.G., A.E., U.M.Z., C.M., B.H., L.S.; data interpretation A.M.C., C.S.W., U.P., C.A.J., M.F., U.M.Z., C.M., B.H., C.D.S., B.W., L.S.; literature search A.M.C., C.S.W., C.A.J., M.F., U.M.Z., A.E.; writing all authors.

Funding Open Access funding enabled and organized by Projekt DEAL. This study was supported by funding from the German Center of Lung Research (DZL), the Comprehensive Pneumology Center (CPC) Munich, the German Research Foundation (DFG; 398577603, TR22), and the Federal Ministry of Education and Research (ESCAPE; 01KI20169A).
Data availability The data discussed in this publication are deposited in NCBI’s Gene Expression Omnibus and are accessible under the GEO Series accession number GSE176405.

Declarations

Ethics approval and consent to participate Nasal curettages from SARS-CoV-2-infected individuals and controls were obtained from participants of HPOS, an observational longitudinal study to assess the impact of COVID-19 in the group of health professionals. This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Commission of the Technical University of Munich (ethics vote no. AZ 175/20 s). Informed consent was obtained from all individual participants included in the study prior to participation (Table 1). In vivo mouse study experiments were pre-registered at www.animalstudyregistry.org (study title “Effect of drug on ACE2 levels in mice”; https://doi.org/10.17590/asr.0000225).

Conflict of interest Dr. Jakwerth reports grants from Federal Ministry of Education and Research, grants from European Institute of Innovation & Technology (EIT), during the conduct of the study. Mr. Feuerherd reports personal fees from Helmholtz Zentrum München and Dr. Höhne AG, outside the submitted work. Dr. Spinner reports grants, personal fees, non-financial support, and other from AbbVie, grants, personal fees, non-financial support, and other from Apeiron, personal fees from Formycon, grants, personal fees, non-financial support, and other from Gilead Sciences, grants, personal fees, and other from Eli Lilly, grants, personal fees, non-financial support, and other from Janssen-Cilag, grants, personal fees, non-financial support, and other from GSK/ViViD Healthcare, grants, personal fees, non-financial support, and other from MSD, outside the submitted work. Prof. Dr. Buch reports personal fees from Virometix AG, other from Virometix AG, other from Trials24 GmbH, other from Clemedi AG, outside the submitted work. Prof. Dr. Protzer reports grants from the Federal Ministry of Education and Research, the German Center for Infection Research (DGZIF), the German Research Foundation (DFG), the European Union via Horizon 2020, and the Bavarian Research Foundation during conduct of the study. She receives personal fees as an ad hoc scientific advisor from Abbvie, Arbutus, Gilead, GSK, Johnson & Johnson, Vaccitec. Prof. Dr. Schmidt-Weber reports grants from German Center for Lung Research (DZL), grants from Comprehensive Pulmonary Lung Center (CPC) Munich during the conduct of the study. Personal fees from Allergopharma and Bencard, outside the submitted work. Dr. Zissler reports grants from Federal Ministry of Education and Research, during the conduct of the study. Dr. Chaker reports grants for clinical studies and research and other from Allergopharma, ALK Abello, AstraZeneca, Bencard / Allergen Therapeutics, ASIT Biotech, Lofarma, GSK, Novartis, LETI, Immunotek, Roche, Sanofi Genzyme, Zeller, and from the European Institute of Technology (EIT); has received travel support from the European Academy of Allergy and Clinical Immunology (EAACI), DGAKI, all outside the submitted work. In addition, Drs. Jakwerth, Feuerherd, Protzer, Schmidt-Weber, Zissler, and Chaker are named as inventors on the patent application “Novel approaches for treatment of SARS-CoV-2 Infection in a patient.” Mr. Guerth, Ms. Oelsner, Dr. Schellhammer, Ms. Giglberger, Ms. Pechtold, Dr. Jerin, Ms. Kugler, Dr. Mogler, Dr. Haller, Ms. Erb, and Prof. Dr. Wollenberg have nothing to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615. https://doi.org/10.1056/NEJMoa2034577
2. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD (2020) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75:1730–1741. https://doi.org/10.1111/all.14238
3. Callaway E (2021) Heavily mutated Omicron variant puts scientists on alert. Nature 600:21. https://doi.org/10.1038/d41586-021-03552-w
4. Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaeler-Babajew DJ, DaSilva J, Muecksfh F, Gaebler C et al (2021) Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med. https://doi.org/10.1056/NEJMoa2105000
5. Schmidt F, Weisblum Y, Muecksch F, Hoffmann HH, Michailidis E, Lorenzi JCC, Mendoza P, Rutkowska M, Bednarski E, Brander C et al (2020) Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 217. https://doi.org/10.1084/jem.20201181
6. Sokolowska M, Lukasik ZM, Agache I, Akdis CA, Akdis D, Akdis M, Barick W, Brough HA, Eliejszewicz A et al (2020) Immunology of COVID-19: mechanisms, clinical outcome, diagnostics, and perspectives—a report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy 75:2445–2476. https://doi.org/10.1111/all.14462
7. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W et al (2021) Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76:428–455. https://doi.org/10.1111/all.14657
8. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(271–280)c278. https://doi.org/10.1016/j.cell.2020.02.052
9. Matsuyma S, Nagata N, Shirato K, Kawai M, Takeda M, Taguchi F (2010) Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 84:12658–12664. https://doi.org/10.1128/JVI.01542-10
10. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450–454. https://doi.org/10.1038/nature02145
11. Diamond B (2020) The renin-angiotensin system: an integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications. J Exp Med 217. https://doi.org/10.1084/jem.20201000
12. Schmaier AH (2016) The contact activation and kalikrein/kinin systems: pathophysiological and physiologic activities. J Thromb Haemost 14:28–39. https://doi.org/10.1111/jth.13194
13. Stukalov A, Girault V, Grass V, Karayel O, Bergant V, Urban C, Haas DA, Huang Y, Oubraham L, Wang A, et al. (2021) Multi-level proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature. https://doi.org/10.1038/s41586-021-03493-4
14. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H et al (2005) Angiotensin-converting
enzyme 2 protects from severe acute lung failure. Nature 436:112–116. https://doi.org/10.1038/nature03712
15. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ (2018) The ACE2/Angiotensin-(1–7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1–7). Physiol Rev 98:505–553. https://doi.org/10.1152/physrev.00023.2016
16. Vickers C, Hales P, Kauschik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F et al (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277:14838–14843. https://doi.org/10.1074/jbc.M200581200
17. van de Veerdonk FL, Netea MG, van Deuren M, van der Hoeven H (2020) Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife 9. https://doi.org/10.7554/eLife.57555
18. Shen B, Harrison-Bernard LM, Fuller AJ, Vanderpool V, Saifudeen Z, El-Dahr SS (2018) The ACE2/enzyme 2 protects from severe acute lung failure. Nature 436:112–116. https://doi.org/10.1038/nature03712
19. Burch RM, Axelrod J (1987) Dissociation of bradykinin-induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: evidence for G protein regulation of phospholipase A2. Proc Natl Acad Sci U S A 84:6374–6378. https://doi.org/10.1073/pnas.84.18.6374
20. Slivka SR, Insel PA (1988) Phorbol ester and neomycin dissociate bradykinin receptor-mediated arachidonic acid release and polyphosphoinositide hydrolysis in Madin-Darby canine kidney cells. Evidence that bradykinin mediates noninterdependent activation of phospholipases A2 and C. J Biol Chem 263:14640–14647
21. Yu HS, Lin TH, Tang CH (2013) Involvement of intercellular adhesion molecule-1 up-regulation in bradykinin promotes cell motility in human prostate cancers. Int J Mol Sci 14:13329–13345. https://doi.org/10.3390/ijms140713329
22. Chen S, Zhang L, Xu R, Ti Y, Zhao Y, Zhou L, Zhao J (2017) BDKRB2 +9/-9 bp polymorphisms influence BDKRB2 expression levels and NO production in knee osteoarthritis. Exp Biol Med (Maywood) 242:422–428. https://doi.org/10.1177/1535370216625471
23. Souza PPC, Lundberg P, Lundgren I, Magalhaes FAC, Costa-Neto CM, Lerner UH (2019) Activation of Toll-like receptor 2 induces B1 and B2 kinin receptors in human gingival fibroblasts and in mouse gingiva. Sci Rep 9:2973. https://doi.org/10.1038/s41598-018-37777-z
24. Imai Y, Kubo K, Penninger JM (2008) The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol 93:543–548. https://doi.org/10.1113/expphysiol.2007.040488
25. Jia H (2016) Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock 46:239–248. https://doi.org/10.1097/SHK.0000000000000633
26. Lipsey M, Persson B, Eriksson O, Blom AM, Fromell K, Hultstrom M, Huber-Lang M, Ekdahl KN, Frithiof R, Nilsson B (2021) The outcome of critically ill COVID-19 patients is linked to thrombin-kinin system: studies in COVID-19. Front Immunol 12;627579. https://doi.org/10.3389/fimmu.2021.627579
27. Mansour E, Palma AC, Ulaf RG, Ribeiro LC, Bernardes AF, Nunes TA, Agrela MV, Bombassaro B, Monfort-Pires M, Camargo RL et al (2021) Safety and outcomes associated with the pharmacological inhibition of the kinin-kallikrein system in severe COVID-19. Viruses 13. https://doi.org/10.3390/v13020309
28. Meini S, Zanichelli A, Sbrojavacca R, Iuri F, Roberts AT, Suffritti C, Tascini C (2020) Understanding the pathophysiology of COVID-19: could the contact system be the key? Front Immunol 11:2014. https://doi.org/10.3389/fimmu.2020.02014
29. Koumandou VL, Scuriolas A (2013) Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms. PLoS One 8:e68074. https://doi.org/10.1371/journal.pone.0068074
30. Mameddou P, Emanuelli C, El-Dahr S (2007) Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol 3:208–221. https://doi.org/10.1038/ncnpneph0444
31. Kitamura N, Kitagawa F, Fukushima D, Takagaki Y, Miyata T, Nakanishi S (1985) Structural organization of the human kininogen gene and a model for its evolution. J Biol Chem 260:8610–8617
32. Kaplan AP, Joseph K, Silverberg M (2002) Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 109:195–209. https://doi.org/10.1067/mai.2002.121316
33. de Maat S, de Mast Q, Danser AHJ, van de Veerdonk FL, Maas C (2020) Impaired breakdown of bradykinin and its metabolites as a possible cause for pulmonary edema in COVID-19 infection. Semin Thromb Hemost 46:835–837. https://doi.org/10.1055/s-0040-1712960
34. Garvin MR, Alvarez C, Miller JJ, Prates ET, Walker AM, Amos BK, Mast AE, Justice A, Aronow B, Jacobson D (2020) A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife 9. https://doi.org/10.7554/eLife.59177
35. Kaplan AP, Ghebrehiwet B (2021) Pathways for bradykinin formation and interrelationship with complement as a cause of edematous lung in COVID-19 patients. J Allergy Clin Immunol 147:507–509. https://doi.org/10.1016/j.jaci.2020.01.025
36. Roche JA, Roche R (2020) A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications. FASEB J 34:7265–7269. https://doi.org/10.1096/fj.202000967
37. Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B (2010) IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor Nkp46. Nat Immunol 11:1030–1038. https://doi.org/10.1038/ni.1947
38. Sunnag W, Huang N, Becavin C, Berg M, Queen R, Litvinukova M, Talavera-Lopez C, Maatz H, Reichart D, Sampaziotis F et al (2020) SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med 26:681–687. https://doi.org/10.1038/s41591-020-0868-6
39. Bas M, Bier H, Greve J, Kojda G, Hofmann TK (2006) Novel pharmacotherapy of acute hereditary angioedema with bradykinin B2-receptor antagonist icatibant. Allergy 61:1490–1492. https://doi.org/10.1111/j.1398-9995.2006.01197.x
40. Yoshikawa T, Hill TE, Yoshikawa N, Popov VL, Galindo CL, Garner NR, Peters CJ, Tseng CT (2010) Dynamic innate immune pathways and treatment of cytokine storm in COVID-19. Sig Transduct Target Ther 6:255. https://doi.org/10.1038/s41492-021-00679-0
41. Leach JK, Spencer K, Mascelli M, McCauley TG (2015) Pharmacokinetics of single and repeat doses of icatibant. Clin Pharmacol Drug Dev 4:105–111. https://doi.org/10.1002/cpdd.138
42. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/s0140-6736(20)30183-5
43. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Yang X, Wang Y, Song B, Gu X et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
cells via COX-2-derived prostanooids. Am J Physiol Lung Cell Mol Physiol 283:L612-618. https://doi.org/10.1152/ajplung.00483.2001
56. Norelli M, Camisa B, Barbiere G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P et al (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24:739–748. https://doi.org/10.1038/s41591-018-0036-4
57. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP (2020) The triinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. https://doi.org/10.1038/s41575-020-0311-8
58. Zmora P, Hoffmann M, Kollmuss H, Moldenhauer AS, Danov O, Braun A, Winkler M, Schughart K, Pohlmann S (2018) TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1. J Biol Chem 293:13863–13873. https://doi.org/10.1074/jbc.RA118.001273
59. Kishimoto M, Uemura K, Sanaki T, Sato A, Hall WW, Kariwa H, Orba Y, Sawa H, Sasaki M (2021) TMPRSS11D and TMPRSS13 activate the SARS-CoV-2 spike protein Viruses 13. https://doi.org/10.3390/v13030384
60. Han DP, Lohani M, Cho MW (2007) Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. J Virol 81:12029–12039. https://doi.org/10.1128/JVI.00315-07
61. Busse PJ, Farkas H, Banerji A, Lumry WR, Longhurst HJ, Sexton DJ, Riedl MA (2019) Lenalidomub for the prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency: a review of preclinical and phase I studies. BioDrugs 33:33–43. https://doi.org/10.1007/s40259-018-0325-y
62. van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, van der Hoeven HG, Maas C, Netea MG, Bruggemann RJM (2020) Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open 3:e2017708. https://doi.org/10.1001/jamanetworkopen.2020.17708
63. Abdel Hameid R, Cormet-Boyaka E, Kuebler WM, Uddin M, Berdiev BK (2021) SARS-CoV-2 may hijack GPCR signaling pathways to dysregulate lung ion and fluid transport. Am J Physiol Lung Cell Mol Physiol 320:L430-L435. https://doi.org/10.1152/ajplung.00499.2020
64. Stukalov A, Girovli V, Grass V, Karayel O, Bergant V, Urban C, Haas DA, Huang Y, Oubraham L, Wang A et al (2021) Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature 594:246–252. https://doi.org/10.1038/s41586-021-03493-4

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Constance A. Jakwerth1, 2, Martin Feuerherd3, Ferdinand M. Guerth1, Madlen Oelsner1, Linda Schellhammer1, Johanna Giglberger4, 6, Lisa Pechtold6, Claudia Jerin1, 6, Luisa Kugler6, Carolin Mogler4, Bernhard Haller3, Anna Erb1, Barbara Wollenberg6, Christoph D. Spinner1, Thorsten Buch3, Ulrike Protzer2, Carsten B. Schmidt-Weber1, 2, Ulrich M. Zissler1, Adam M. Chaker1, 6

1 Center of Allergy & Environment (ZAMU), Technical University of Munich and Helmholtz Center Munich, German Research Center for Environmental Health, Member of the German Center for Lung Research (DZL), Biedersteiner Str. 29, 8020 Munich, Germany
2 Institute of Virology, Technical University of Munich/Helmholtz Zentrum München, German Center for Infectiology Research (DZIF), Munich partner site, Munich, Germany
3 Institute of Laboratory Animal Science, University of Zurich, Zurich, Switzerland
Institute of Pathology, Technical University Munich, Munich, Germany

Institute of Medical Informatics, Statistics and Epidemiology, Medical School, Technical University of Munich, Munich, Germany

Department of Otorhinolaryngology and Head and Neck Surgery, Medical School, Technical University of Munich, Munich, Germany

Department of Internal Medicine II, University Hospital Rechts Der Isar, Medical School, Technical University of Munich, Munich, Germany